•New data demonstrates BTX 1801 eliminates methicillin-resistant Staphylococcus aureus(‘MRSA’ or ‘Golden Staph’) from human skin explants infected with MRSA
•New data also confirms synthetic CBD’s novel mechanism of action, where treatment with CBD rapidly disrupts the bacteria’s membrane resulting in cell death
•The studies provide support for the recently commenced BTX 1801 Phase 2a clinical study, which is on target for completion in 4Q CY2020
•Botanix is participating in the 2020 ASX Small & Mid-Cap Virtual Conference and the presentation is attached to this release
Ann: New Antimicrobial Data and Conference Presentation, page-4
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.020(5.26%) |
Mkt cap ! $651.6M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 36.0¢ | $1.832M | 5.001M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 1023317 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 3589 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |